<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BESIVANCE- besifloxacin suspension </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Besivance safely and effectively. See full prescribing information for Besivance. <br><br>Besivance® (besifloxacin ophthalmic suspension) 0.6%<br>Sterile topical ophthalmic drops<br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indications and Usage (<a href="#i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9">1</a>)                                   9/2012 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Besivance® (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible isolates of the following bacteria: </p>
<p class="Highlighta"><span class="Italics">Aerococcus viridans </span>*, CDC coryneform group G, <span class="Italics">Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa *, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*,Staphylococcus warneri*, Streptococcus mitis </span>group<span class="Italics">, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*</span> </p>
<p class="Highlighta">*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (<a href="#i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days. (<a href="#i4i_dosage_admin_id_402d83f4-5330-4e95-8520-8e45c72daefc">2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">7.5 mL size bottle filled with 5 mL of besifloxacin ophthalmic suspension, 0.6% (<a href="#i4i_dosage_form_strength_id_f87d6e91-955f-4cc5-91a7-bc1f3ccebf29">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#i4i_contraindications_id_d2253e7d-f2f4-4931-b3ef-4d53dfe16078">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">Topical Ophthalmic Use Only. (<a href="#i4i_section_id_2a94f8bc-7cd5-4334-8cd2-6752894054a8">5.1</a>) </p>
<p class="Highlighta">Growth of Resistant Organisms with Prolonged Use. (<a href="#i4i_section_id_80493378-4620-4df2-89be-e276d9915c0b">5.2</a>) </p>
<p class="Highlighta">Avoidance of Contact Lenses. Patients should not wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with Besivance (<a href="#i4i_section_id_098b7f56-66ee-40bc-86e7-a62c2c4186cb">5.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reaction reported in 2% of patients treated with Besivance was <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival redness</span>. (<a href="#i4i_adverse_effects_id_e0d8e43f-3eaa-4a22-b586-b6a9c0d29bdd">6</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated at 1-800-323-0000 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Topical Ophthalmic Use Only </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Growth of Resistant Organisms with Prolonged Use </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Avoidance of Contact Lenses </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-9.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Besivance<span class="Sup">®</span> (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible isolates of the following bacteria:</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Aerococcus viridans*</span></span></p>
<p>CDC coryneform group G</p>
<p><span class="Italics">Corynebacterium pseudodiphtheriticum*</span></p>
<p><span class="Italics">Corynebacterium striatum*</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Moraxella catarrhalis*</span></span></p>
<p><span class="Italics">Moraxella lacunata*</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Pseudomonas aeruginosa</span></span></p>
<p><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Staphylococcus hominis*</span></p>
<p><span class="Italics">Staphylococcus lugdunensis*</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Staphylococcus warneri*</span></span></p>
<p><span class="Italics">Streptococcus mitis</span> group </p>
<p><span class="Italics">Streptococcus oralis</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus salivarius*</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_402d83f4-5330-4e95-8520-8e45c72daefc"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Invert closed bottle and shake once before use.</p>
<p>Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_f87d6e91-955f-4cc5-91a7-bc1f3ccebf29"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">7.5 mL bottle filled with 5 mL of besifloxacin ophthalmic suspension, 0.6%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d2253e7d-f2f4-4931-b3ef-4d53dfe16078"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_b2b7bce9-c961-497e-9255-986cadb7d4cc"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a94f8bc-7cd5-4334-8cd2-6752894054a8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Topical Ophthalmic Use Only </h2>
<p class="First">NOT FOR INJECTION INTO THE EYE.</p>
<p>Besivance is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80493378-4620-4df2-89be-e276d9915c0b"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Growth of Resistant Organisms with Prolonged Use </h2>
<p class="First">As with other anti-infectives, prolonged use of Besivance (besifloxacin ophthalmic suspension) 0.6% may result in overgrowth of non-susceptible organisms, including fungi. If super-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_098b7f56-66ee-40bc-86e7-a62c2c4186cb"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Avoidance of Contact Lenses </h2>
<p class="First">Patients should not wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with Besivance .</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e0d8e43f-3eaa-4a22-b586-b6a9c0d29bdd"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to Besivance in approximately 1,000 patients between 1 and 98 years old with clinical signs and symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p>The most frequently reported ocular adverse reaction was <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival redness</span>, reported in approximately 2% of patients.</p>
<p>Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_f3069b27-c20a-4f8c-b9e1-4b61eb4a2497"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_65ead455-afd2-4267-87ec-9893f5c2e75f"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C.</span> Oral doses of besifloxacin up to 1000 mg/kg/day were not associated with visceral or skeletal malformations in rat pups in a study of embryo-fetal development, although this dose was associated with maternal toxicity (reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) and maternal mortality. Increased post-implantation loss, decreased fetal body weights, and decreased fetal ossification were also observed. At this dose, the mean C<span class="Sub">max</span> in the rat dams was approximately 20 mcg/mL, &gt;45,000 times the mean plasma concentrations measured in humans. The No Observed Adverse Effect Level (NOAEL) for this embryo-fetal development study was 100 mg/kg/day (C<span class="Sub">max</span>, 5 mcg/mL, &gt;11,000 times the mean plasma concentrations measured in humans).</p>
<p>In a prenatal and postnatal development study in rats, the NOAELs for both fetal and maternal toxicity were also 100 mg/kg/day. At 1000 mg/kg/day, the pups weighed significantly less than controls and had a reduced neonatal survival rate. Attainment of developmental landmarks and sexual maturation were delayed, although surviving pups from this dose group that were reared to maturity did not demonstrate deficits in behavior, including activity, learning and memory, and their reproductive capacity appeared normal.</p>
<p>Since there are no adequate and well-controlled studies in pregnant women, Besivance  should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e4b68c41-6c9d-4fe7-80fd-ec3eb6dcac2f"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Besifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Besivance is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9a1f0a8c-f171-409c-a6da-673667b8829d"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Besivance<span class="Sup">®</span> in infants below one year of age have not been established. The efficacy of Besivance in treating bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> in pediatric patients one year or older has been demonstrated in controlled clinical trials<span class="Italics"> [see <a href="#i4i_clinical_studies_id_108cbde0-11b4-4b87-bb16-48b6ee85b5d9">Clinical Studies (14)</a>] </span>.</p>
<p>There is no evidence that the ophthalmic administration of quinolones has any effect on weight bearing joints, even though systemic administration of some quinolones has been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_65a69e22-3588-488d-b541-5da873d435b3"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall differences in safety and effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d318165f-72b0-4fb9-95f7-90cfc4c6d0cd"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Besivance (besifloxacin ophthalmic suspension) 0.6%, is a sterile ophthalmic suspension of besifloxacin formulated with DuraSite<span class="Sup">®</span>* (polycarbophil, edetate disodium dihydrate and sodium chloride). Each mL of Besivance contains 6.63 mg besifloxacin hydrochloride equivalent to 6 mg besifloxacin base. It is an 8-chloro fluoroquinolone anti-infective for topical ophthalmic use.</p>
<div class="Figure">
<a name="id454"></a><img alt="Besifloxacin hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3e6d688-7e5e-4ca3-b27e-79756c322a32&amp;name=964c5a85-3cc2-4d53-ab7d-f8d205d997e4-01.jpg">
</div>
<p>C<span class="Sub">19</span>H<span class="Sub">21</span>ClFN<span class="Sub">3</span>O<span class="Sub">3</span>•HCl</p>
<p>Mol Wt 430.30</p>
<p>Chemical Name:(+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1- cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.</p>
<p>Besifloxacin hydrochloride is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish-white powder.</p>
<p><span class="Bold">Each mL Contains:</span></p>
<p><span class="Bold">Active: </span>besifloxacin 0.6% (6 mg/mL);</p>
<p><span class="Bold">Preservative: </span>benzalkonium chloride 0.01%</p>
<p><span class="Bold">Inactives: </span>polycarbophil, mannitol, poloxamer 407, sodium chloride, edetate disodium dihydrate, sodium hydroxide and water for injection.</p>
<p>Besivance is an isotonic suspension with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_bab842f2-5e3d-41f6-9e9a-e244a892b164"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_afd0c276-cc2b-45fb-8cdf-ec33ba63847f"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Besifloxacin is a fluoroquinolone antibacterial <span class="Italics">[see <a href="#i4i_microbiology_id_18507b37-5077-419a-bb72-e5ca407831de">Clinical Pharmacology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_cf911deb-46b9-4030-8146-1370c81f6852"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Plasma concentrations of besifloxacin were measured in adult patients with suspected bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> who received Besivance bilaterally three times a day (16 doses total). Following the first and last dose, the maximum plasma besifloxacin concentration in each patient was less than 1.3 ng/mL. The mean besifloxacin C<span class="Sub">max</span> was 0.37 ng/mL on day 1 and 0.43 ng/mL on day 6. The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_18507b37-5077-419a-bb72-e5ca407831de"></a><a name="section-9.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Besifloxacin is an 8-chloro fluoroquinolone with a N-1 cyclopropyl group. The compound has activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA. Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division. Besifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).</p>
<p>The mechanism of action of fluoroquinolones, including besifloxacin, is different from that of aminoglycoside, macrolide, and <span class="Italics">β</span>-lactam antibiotics. Therefore, besifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to besifloxacin. <span class="Italics">In vitro</span> studies demonstrated cross-resistance between besifloxacin and some fluoroquinolones.</p>
<p><span class="Italics">In vitro</span> resistance to besifloxacin develops via multiple-step mutations and occurs at a general frequency of &lt; 3.3 x 10<span class="Sup">-10</span> for <span class="Italics">Staphylococcus aureus</span> and &lt; 7 x 10<span class="Sup">-10</span> for <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>Besifloxacin has been shown to be active against most isolates of the following bacteria both <span class="Italics">in vitro</span> and in conjunctival <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> treated in clinical trials as described in the <a href="#i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9">INDICATIONS AND USAGE</a> section:</p>
<p><span class="Italics">Aerococcus viridans*</span>, CDC coryneform group G, <span class="Italics">Corynebacterium pseudodiphtheriticum*, C. striatum*, Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis*</span>, <span class="Italics">M. lacunata*</span>, <span class="Italics">Pseudomonas aeruginosa*</span>, <span class="Italics">Staphylococcus aureus</span>, <span class="Italics">S. epidermidis</span>, <span class="Italics">S. hominis*</span>, <span class="Italics">S. lugdunensis*</span>, <span class="Italics">S. warneri*</span>, <span class="Italics">Streptococcus mitis</span> group, <span class="Italics">S. oralis</span>, <span class="Italics">S. pneumoniae</span>, <span class="Italics">S. salivarius*</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_5286e1d7-f77e-4ad1-8a88-6a6b6e89f858"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8cdb0088-5f2b-4726-a52e-d124b3b978ba"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to determine the carcinogenic potential of besifloxacin have not been performed.</p>
<p>No <span class="Italics">in vitro</span> mutagenic activity of besifloxacin was observed in an Ames test (up to 3.33 mcg/plate) on bacterial tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> TA98, TA100, TA1535, TA1537 and <span class="Italics">Escherichia coli</span> WP2uvrA. However, it was mutagenic in <span class="Italics">S. typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA102 and <span class="Italics">E. coli</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2(pKM101). Positive responses in these <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> have been observed with other quinolones and are likely related to topoisomerase inhibition.</p>
<p>Besifloxacin induced chromosomal aberrations in CHO cells <span class="Italics">in vitro</span> and it was positive in an <span class="Italics">in vivo</span> mouse micronucleus assay at oral doses ≥ 1500 mg/kg. Besifloxacin did not induce unscheduled DNA synthesis in hepatocytes cultured from rats given the test compound up to 2,000 mg/ kg by the oral route. In a fertility and early embryonic development study in rats, besifloxacin did not impair the fertility of male or female rats at oral doses of up to 500 mg/kg/day. This is over 10,000 times higher than the recommended total daily human ophthalmic dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_108cbde0-11b4-4b87-bb16-48b6ee85b5d9"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a randomized, double-masked, vehicle controlled, multicenter clinical trial, in which patients 1-98 years of age were dosed 3 times a day for 5 days, Besivance was superior to its vehicle in patients with bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Clinical resolution was achieved in 45% (90/198) for the Besivance treated group versus 33% (63/191) for the vehicle treated group (difference 12%, 95% CI 3% - 22%). Microbiological outcomes demonstrated a statistically significant eradication rate for causative pathogens of 91% (181/198) for the Besivance treated group versus 60% (114/191) for the vehicle treated group (difference 31%, 95% CI 23% - 40%). Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_dfb0c174-0858-478a-9b98-e5261d8c0686"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Besivance<span class="Sup">®</span> (besifloxacin ophthalmic suspension) 0.6%, is supplied as a sterile ophthalmic suspension in a white low density polyethylene (LDPE) bottle with a controlled dropper tip and tan polypropylene cap. Tamper evidence is provided with a shrink band around the cap and neck area of the package.</p>
<p>5 mL in 7.5 mL bottle</p>
<p><span class="Bold">NDC </span>24208-446-05</p>
<p><br><span class="Bold">Storage: </span>Store at 15°- 25°C (59° - 77°F). Protect from Light. Invert closed bottle and shake once before use.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7b341888-7e7e-48f6-9cdb-9de70d516244"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to avoid contaminating the applicator tip with material from the eye, fingers or other source.</p>
<p>Although Besivance is not intended to be administered systemically, quinolones administered systemically have been associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>Patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Besivance or other antibacterial drugs in the future.</p>
<p>Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with Besivance.</p>
<p>Patients should be advised to thoroughly wash hands prior to using Besivance.</p>
<p>Patients should be instructed to invert closed bottle (upside down) and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back, and with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s).</p>
<p>Manufactured by: Bausch &amp; Lomb Incorporated<br>Tampa, Florida 33637</p>
<p>Besivance<span class="Sup">®</span> is a registered trademark of Bausch &amp; Lomb Incorporated.</p>
<p>©Bausch &amp; Lomb Incorporated</p>
<p>U.S. Patent Nos. 6,685,958; 6,699,492; 5,447,926</p>
<p>*DuraSite is a trademark of InSite Vision Incorporated</p>
<p>9142605 (flat)</p>
<p>9142705 (folded)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_27e2bfd9-1a3a-4100-97d6-b859c30feb52"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id628"></a><img alt="5 mL carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3e6d688-7e5e-4ca3-b27e-79756c322a32&amp;name=964c5a85-3cc2-4d53-ab7d-f8d205d997e4-02.jpg">
</div>
<p class="First">NDC 24208-446-05 </p>
<p>BAUSCH + LOMB</p>
<p><span class="Bold">Besivance<span class="Sup">®</span></span></p>
<p><span class="Bold">besifloxacin ophthalmic </span></p>
<p><span class="Bold">suspension, 0.6% </span></p>
<p><span class="Bold">Rx only </span><br><span class="Bold">Sterile </span></p>
<p><span class="Bold">FOR OPHTHALMIC </span></p>
<p><span class="Bold">USE ONLY.</span></p>
<p><span class="Bold">5 mL</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BESIVANCE 		
					</strong><br><span class="contentTableReg">besifloxacin suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-446</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BESIFLOXACIN</strong> (BESIFLOXACIN) </td>
<td class="formItem">BESIFLOXACIN</td>
<td class="formItem">6 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYCARBOPHIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 407</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-446-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-446-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022308</td>
<td class="formItem">05/28/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-446)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6d9f530d-ab66-4836-91e2-6f260f832bac</div>
<div>Set id: a3e6d688-7e5e-4ca3-b27e-79756c322a32</div>
<div>Version: 9</div>
<div>Effective Time: 20120901</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BESIVANCE- besifloxacin suspension </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Besivance safely and effectively. See full prescribing information for Besivance. <br><br>Besivance® (besifloxacin ophthalmic suspension) 0.6%<br>Sterile topical ophthalmic drops<br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indications and Usage (<a href="#i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9">1</a>)                                   9/2012 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Besivance® (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible isolates of the following bacteria: </p>
<p class="Highlighta"><span class="Italics">Aerococcus viridans </span>*, CDC coryneform group G, <span class="Italics">Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa *, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*,Staphylococcus warneri*, Streptococcus mitis </span>group<span class="Italics">, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*</span> </p>
<p class="Highlighta">*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (<a href="#i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days. (<a href="#i4i_dosage_admin_id_402d83f4-5330-4e95-8520-8e45c72daefc">2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">7.5 mL size bottle filled with 5 mL of besifloxacin ophthalmic suspension, 0.6% (<a href="#i4i_dosage_form_strength_id_f87d6e91-955f-4cc5-91a7-bc1f3ccebf29">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#i4i_contraindications_id_d2253e7d-f2f4-4931-b3ef-4d53dfe16078">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">Topical Ophthalmic Use Only. (<a href="#i4i_section_id_2a94f8bc-7cd5-4334-8cd2-6752894054a8">5.1</a>) </p>
<p class="Highlighta">Growth of Resistant Organisms with Prolonged Use. (<a href="#i4i_section_id_80493378-4620-4df2-89be-e276d9915c0b">5.2</a>) </p>
<p class="Highlighta">Avoidance of Contact Lenses. Patients should not wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with Besivance (<a href="#i4i_section_id_098b7f56-66ee-40bc-86e7-a62c2c4186cb">5.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reaction reported in 2% of patients treated with Besivance was <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival redness</span>. (<a href="#i4i_adverse_effects_id_e0d8e43f-3eaa-4a22-b586-b6a9c0d29bdd">6</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated at 1-800-323-0000 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Topical Ophthalmic Use Only </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Growth of Resistant Organisms with Prolonged Use </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Avoidance of Contact Lenses </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-9.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Besivance<span class="Sup">®</span> (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible isolates of the following bacteria:</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Aerococcus viridans*</span></span></p>
<p>CDC coryneform group G</p>
<p><span class="Italics">Corynebacterium pseudodiphtheriticum*</span></p>
<p><span class="Italics">Corynebacterium striatum*</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Moraxella catarrhalis*</span></span></p>
<p><span class="Italics">Moraxella lacunata*</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Pseudomonas aeruginosa</span></span></p>
<p><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Staphylococcus hominis*</span></p>
<p><span class="Italics">Staphylococcus lugdunensis*</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Staphylococcus warneri*</span></span></p>
<p><span class="Italics">Streptococcus mitis</span> group </p>
<p><span class="Italics">Streptococcus oralis</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus salivarius*</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_402d83f4-5330-4e95-8520-8e45c72daefc"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Invert closed bottle and shake once before use.</p>
<p>Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_f87d6e91-955f-4cc5-91a7-bc1f3ccebf29"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">7.5 mL bottle filled with 5 mL of besifloxacin ophthalmic suspension, 0.6%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d2253e7d-f2f4-4931-b3ef-4d53dfe16078"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_b2b7bce9-c961-497e-9255-986cadb7d4cc"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a94f8bc-7cd5-4334-8cd2-6752894054a8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Topical Ophthalmic Use Only </h2>
<p class="First">NOT FOR INJECTION INTO THE EYE.</p>
<p>Besivance is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80493378-4620-4df2-89be-e276d9915c0b"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Growth of Resistant Organisms with Prolonged Use </h2>
<p class="First">As with other anti-infectives, prolonged use of Besivance (besifloxacin ophthalmic suspension) 0.6% may result in overgrowth of non-susceptible organisms, including fungi. If super-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_098b7f56-66ee-40bc-86e7-a62c2c4186cb"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Avoidance of Contact Lenses </h2>
<p class="First">Patients should not wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with Besivance .</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e0d8e43f-3eaa-4a22-b586-b6a9c0d29bdd"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to Besivance in approximately 1,000 patients between 1 and 98 years old with clinical signs and symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p>The most frequently reported ocular adverse reaction was <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival redness</span>, reported in approximately 2% of patients.</p>
<p>Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_f3069b27-c20a-4f8c-b9e1-4b61eb4a2497"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_65ead455-afd2-4267-87ec-9893f5c2e75f"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C.</span> Oral doses of besifloxacin up to 1000 mg/kg/day were not associated with visceral or skeletal malformations in rat pups in a study of embryo-fetal development, although this dose was associated with maternal toxicity (reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) and maternal mortality. Increased post-implantation loss, decreased fetal body weights, and decreased fetal ossification were also observed. At this dose, the mean C<span class="Sub">max</span> in the rat dams was approximately 20 mcg/mL, &gt;45,000 times the mean plasma concentrations measured in humans. The No Observed Adverse Effect Level (NOAEL) for this embryo-fetal development study was 100 mg/kg/day (C<span class="Sub">max</span>, 5 mcg/mL, &gt;11,000 times the mean plasma concentrations measured in humans).</p>
<p>In a prenatal and postnatal development study in rats, the NOAELs for both fetal and maternal toxicity were also 100 mg/kg/day. At 1000 mg/kg/day, the pups weighed significantly less than controls and had a reduced neonatal survival rate. Attainment of developmental landmarks and sexual maturation were delayed, although surviving pups from this dose group that were reared to maturity did not demonstrate deficits in behavior, including activity, learning and memory, and their reproductive capacity appeared normal.</p>
<p>Since there are no adequate and well-controlled studies in pregnant women, Besivance  should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e4b68c41-6c9d-4fe7-80fd-ec3eb6dcac2f"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Besifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Besivance is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9a1f0a8c-f171-409c-a6da-673667b8829d"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Besivance<span class="Sup">®</span> in infants below one year of age have not been established. The efficacy of Besivance in treating bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> in pediatric patients one year or older has been demonstrated in controlled clinical trials<span class="Italics"> [see <a href="#i4i_clinical_studies_id_108cbde0-11b4-4b87-bb16-48b6ee85b5d9">Clinical Studies (14)</a>] </span>.</p>
<p>There is no evidence that the ophthalmic administration of quinolones has any effect on weight bearing joints, even though systemic administration of some quinolones has been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_65a69e22-3588-488d-b541-5da873d435b3"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall differences in safety and effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d318165f-72b0-4fb9-95f7-90cfc4c6d0cd"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Besivance (besifloxacin ophthalmic suspension) 0.6%, is a sterile ophthalmic suspension of besifloxacin formulated with DuraSite<span class="Sup">®</span>* (polycarbophil, edetate disodium dihydrate and sodium chloride). Each mL of Besivance contains 6.63 mg besifloxacin hydrochloride equivalent to 6 mg besifloxacin base. It is an 8-chloro fluoroquinolone anti-infective for topical ophthalmic use.</p>
<div class="Figure">
<a name="id454"></a><img alt="Besifloxacin hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3e6d688-7e5e-4ca3-b27e-79756c322a32&amp;name=964c5a85-3cc2-4d53-ab7d-f8d205d997e4-01.jpg">
</div>
<p>C<span class="Sub">19</span>H<span class="Sub">21</span>ClFN<span class="Sub">3</span>O<span class="Sub">3</span>•HCl</p>
<p>Mol Wt 430.30</p>
<p>Chemical Name:(+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1- cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.</p>
<p>Besifloxacin hydrochloride is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish-white powder.</p>
<p><span class="Bold">Each mL Contains:</span></p>
<p><span class="Bold">Active: </span>besifloxacin 0.6% (6 mg/mL);</p>
<p><span class="Bold">Preservative: </span>benzalkonium chloride 0.01%</p>
<p><span class="Bold">Inactives: </span>polycarbophil, mannitol, poloxamer 407, sodium chloride, edetate disodium dihydrate, sodium hydroxide and water for injection.</p>
<p>Besivance is an isotonic suspension with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_bab842f2-5e3d-41f6-9e9a-e244a892b164"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_afd0c276-cc2b-45fb-8cdf-ec33ba63847f"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Besifloxacin is a fluoroquinolone antibacterial <span class="Italics">[see <a href="#i4i_microbiology_id_18507b37-5077-419a-bb72-e5ca407831de">Clinical Pharmacology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_cf911deb-46b9-4030-8146-1370c81f6852"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Plasma concentrations of besifloxacin were measured in adult patients with suspected bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> who received Besivance bilaterally three times a day (16 doses total). Following the first and last dose, the maximum plasma besifloxacin concentration in each patient was less than 1.3 ng/mL. The mean besifloxacin C<span class="Sub">max</span> was 0.37 ng/mL on day 1 and 0.43 ng/mL on day 6. The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_18507b37-5077-419a-bb72-e5ca407831de"></a><a name="section-9.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Besifloxacin is an 8-chloro fluoroquinolone with a N-1 cyclopropyl group. The compound has activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA. Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division. Besifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).</p>
<p>The mechanism of action of fluoroquinolones, including besifloxacin, is different from that of aminoglycoside, macrolide, and <span class="Italics">β</span>-lactam antibiotics. Therefore, besifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to besifloxacin. <span class="Italics">In vitro</span> studies demonstrated cross-resistance between besifloxacin and some fluoroquinolones.</p>
<p><span class="Italics">In vitro</span> resistance to besifloxacin develops via multiple-step mutations and occurs at a general frequency of &lt; 3.3 x 10<span class="Sup">-10</span> for <span class="Italics">Staphylococcus aureus</span> and &lt; 7 x 10<span class="Sup">-10</span> for <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>Besifloxacin has been shown to be active against most isolates of the following bacteria both <span class="Italics">in vitro</span> and in conjunctival <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> treated in clinical trials as described in the <a href="#i4i_indications_id_7bdcb914-a2b8-464a-ac84-24fe7d6b86a9">INDICATIONS AND USAGE</a> section:</p>
<p><span class="Italics">Aerococcus viridans*</span>, CDC coryneform group G, <span class="Italics">Corynebacterium pseudodiphtheriticum*, C. striatum*, Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis*</span>, <span class="Italics">M. lacunata*</span>, <span class="Italics">Pseudomonas aeruginosa*</span>, <span class="Italics">Staphylococcus aureus</span>, <span class="Italics">S. epidermidis</span>, <span class="Italics">S. hominis*</span>, <span class="Italics">S. lugdunensis*</span>, <span class="Italics">S. warneri*</span>, <span class="Italics">Streptococcus mitis</span> group, <span class="Italics">S. oralis</span>, <span class="Italics">S. pneumoniae</span>, <span class="Italics">S. salivarius*</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_5286e1d7-f77e-4ad1-8a88-6a6b6e89f858"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8cdb0088-5f2b-4726-a52e-d124b3b978ba"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to determine the carcinogenic potential of besifloxacin have not been performed.</p>
<p>No <span class="Italics">in vitro</span> mutagenic activity of besifloxacin was observed in an Ames test (up to 3.33 mcg/plate) on bacterial tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> TA98, TA100, TA1535, TA1537 and <span class="Italics">Escherichia coli</span> WP2uvrA. However, it was mutagenic in <span class="Italics">S. typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA102 and <span class="Italics">E. coli</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2(pKM101). Positive responses in these <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> have been observed with other quinolones and are likely related to topoisomerase inhibition.</p>
<p>Besifloxacin induced chromosomal aberrations in CHO cells <span class="Italics">in vitro</span> and it was positive in an <span class="Italics">in vivo</span> mouse micronucleus assay at oral doses ≥ 1500 mg/kg. Besifloxacin did not induce unscheduled DNA synthesis in hepatocytes cultured from rats given the test compound up to 2,000 mg/ kg by the oral route. In a fertility and early embryonic development study in rats, besifloxacin did not impair the fertility of male or female rats at oral doses of up to 500 mg/kg/day. This is over 10,000 times higher than the recommended total daily human ophthalmic dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_108cbde0-11b4-4b87-bb16-48b6ee85b5d9"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a randomized, double-masked, vehicle controlled, multicenter clinical trial, in which patients 1-98 years of age were dosed 3 times a day for 5 days, Besivance was superior to its vehicle in patients with bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Clinical resolution was achieved in 45% (90/198) for the Besivance treated group versus 33% (63/191) for the vehicle treated group (difference 12%, 95% CI 3% - 22%). Microbiological outcomes demonstrated a statistically significant eradication rate for causative pathogens of 91% (181/198) for the Besivance treated group versus 60% (114/191) for the vehicle treated group (difference 31%, 95% CI 23% - 40%). Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_dfb0c174-0858-478a-9b98-e5261d8c0686"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Besivance<span class="Sup">®</span> (besifloxacin ophthalmic suspension) 0.6%, is supplied as a sterile ophthalmic suspension in a white low density polyethylene (LDPE) bottle with a controlled dropper tip and tan polypropylene cap. Tamper evidence is provided with a shrink band around the cap and neck area of the package.</p>
<p>5 mL in 7.5 mL bottle</p>
<p><span class="Bold">NDC </span>24208-446-05</p>
<p><br><span class="Bold">Storage: </span>Store at 15°- 25°C (59° - 77°F). Protect from Light. Invert closed bottle and shake once before use.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7b341888-7e7e-48f6-9cdb-9de70d516244"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to avoid contaminating the applicator tip with material from the eye, fingers or other source.</p>
<p>Although Besivance is not intended to be administered systemically, quinolones administered systemically have been associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>Patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Besivance or other antibacterial drugs in the future.</p>
<p>Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with Besivance.</p>
<p>Patients should be advised to thoroughly wash hands prior to using Besivance.</p>
<p>Patients should be instructed to invert closed bottle (upside down) and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back, and with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s).</p>
<p>Manufactured by: Bausch &amp; Lomb Incorporated<br>Tampa, Florida 33637</p>
<p>Besivance<span class="Sup">®</span> is a registered trademark of Bausch &amp; Lomb Incorporated.</p>
<p>©Bausch &amp; Lomb Incorporated</p>
<p>U.S. Patent Nos. 6,685,958; 6,699,492; 5,447,926</p>
<p>*DuraSite is a trademark of InSite Vision Incorporated</p>
<p>9142605 (flat)</p>
<p>9142705 (folded)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_27e2bfd9-1a3a-4100-97d6-b859c30feb52"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id628"></a><img alt="5 mL carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3e6d688-7e5e-4ca3-b27e-79756c322a32&amp;name=964c5a85-3cc2-4d53-ab7d-f8d205d997e4-02.jpg">
</div>
<p class="First">NDC 24208-446-05 </p>
<p>BAUSCH + LOMB</p>
<p><span class="Bold">Besivance<span class="Sup">®</span></span></p>
<p><span class="Bold">besifloxacin ophthalmic </span></p>
<p><span class="Bold">suspension, 0.6% </span></p>
<p><span class="Bold">Rx only </span><br><span class="Bold">Sterile </span></p>
<p><span class="Bold">FOR OPHTHALMIC </span></p>
<p><span class="Bold">USE ONLY.</span></p>
<p><span class="Bold">5 mL</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BESIVANCE 		
					</strong><br><span class="contentTableReg">besifloxacin suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-446</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BESIFLOXACIN</strong> (BESIFLOXACIN) </td>
<td class="formItem">BESIFLOXACIN</td>
<td class="formItem">6 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYCARBOPHIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 407</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-446-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-446-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022308</td>
<td class="formItem">05/28/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-446)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6d9f530d-ab66-4836-91e2-6f260f832bac</div>
<div>Set id: a3e6d688-7e5e-4ca3-b27e-79756c322a32</div>
<div>Version: 9</div>
<div>Effective Time: 20120901</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
